,
,
, Ouest Against Leukemia' (FHU GOAL)
,
, , p.12
, 13 CHU d'Angers, Service des Maladies du Sang
, , p.15
Service d'h emato-oncologie, 16 INSERM 1066 MINT, p.17 ,
, 18 CHU de Limoges
, Service de M edecine Interne-Maladies Infectieuses
,
Luque Paz contributed equally to this work Funding information French National Institute of Cancer, Award/grant number ,
, Ministère de l'Enseignement Sup erieur et de la Recherche REFERENCES
Molecular diagnostics of myeloproliferative neoplasms, European Journal of Haematology, vol.37, issue.S1, pp.270-279, 2015. ,
DOI : 10.1111/ijlh.12269
URL : https://hal.archives-ouvertes.fr/hal-01916333
A report on the co-occurrence of JAK2V617F and CALR mutations in myeloproliferative neoplasm patients, Annals of Hematology, vol.14, issue.10, pp.865-867, 2015. ,
DOI : 10.1179/102453309X12473408860587
Detection of CALR and MPL Mutations in Low Allelic Burden JAK2 V617F Essential Thrombocythemia, The Journal of Molecular Diagnostics, vol.19, issue.1, pp.92-98, 2017. ,
DOI : 10.1016/j.jmoldx.2016.08.006
URL : https://hal.archives-ouvertes.fr/hal-01766867
mutations are not mutually exclusive; findings from retrospective analysis of a small patient cohort, British Journal of Haematology, vol.369, issue.2, pp.276-278, 2014. ,
DOI : 10.1038/leu.2014.3
V617F allelic burdens, Leukemia & Lymphoma, vol.57, issue.8, pp.1949-1951, 2016. ,
DOI : 10.1182/blood-2013-11-537167
JAK2V617F somatic mutation in the general population: myeloproliferative neoplasm development and progression rate, Haematologica, vol.99, issue.9, pp.1448-1455, 2014. ,
DOI : 10.3324/haematol.2014.107631